Pricing Log in Create free account

Immuneering Corporation (IMRX) vs Sol-Gel Technologies Ltd. (SLGL)

Immuneering Corporation and Sol-Gel Technologies Ltd. are both Biotechnology companies. Immuneering Corporation and Sol-Gel Technologies Ltd. are of similar size ($235.5M and $224.9M). Immuneering Corporation grew revenue faster over the last twelve months: −84.8% against −92.5%. Immuneering Corporation has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−97.1% vs −6,630.2%). Across the 16 metrics below, Immuneering Corporation leads on 8 and Sol-Gel Technologies Ltd. on 8.

Valuation

Metric IMRX SLGL Biotechnology median
P/E n/m n/m 8.50
P/S 732.69 117.08 9.71
P/B 1.22 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 259.82 126.78 9.21
Earnings yield (28.97%) (8.78%) (33.15%)
Free cash flow yield (24.54%) (10.12%) (25.50%)

Profitability

Metric IMRX SLGL Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (52.15%) (40.85%) (56.36%)
Return on assets (47.31%) (35.11%) (48.04%)
Return on invested capital (97.14%) (6,630.24%) 0.00%

Growth

Metric IMRX SLGL Biotechnology median
Revenue growth (TTM) (84.76%) (92.50%) 6.02%
EPS growth (last fiscal year) 37.75% 42.37% 30.26%
Revenue growth, 5-year CAGR — 17.19% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRX SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.47 10.37 4.72
Net debt to EBITDA 2.94 3.23 0.96

Dividend

Metric IMRX SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IMRX SLGL Biotechnology median
Market cap 235.50m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack